Wedbush Maintains Neutral on Vor Biopharma, Raises Price Target to $27

Benzinga · 22h ago
Wedbush analyst Martin Fan maintains Vor Biopharma (NASDAQ:VOR) with a Neutral and raises the price target from $18 to $27.